222 related articles for article (PubMed ID: 29943622)
1. Protection of Kidney Function with Human Antioxidation Protein α
Kristiansson A; Ahlstedt J; Holmqvist B; Brinte A; Tran TA; Forssell-Aronsson E; Strand SE; Gram M; Åkerström B
Antioxid Redox Signal; 2019 May; 30(14):1746-1759. PubMed ID: 29943622
[TBL] [Abstract][Full Text] [Related]
2. Recombinant α
Alattar AG; Kristiansson A; Karlsson H; Vallius S; Ahlstedt J; Forssell-Aronsson E; Åkerström B; Strand SE; Flygare J; Gram M
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371508
[No Abstract] [Full Text] [Related]
3. Kidney Protection with the Radical Scavenger α
Kristiansson A; Örbom A; Vilhelmsson Timmermand O; Ahlstedt J; Strand SE; Åkerström B
Antioxidants (Basel); 2021 Aug; 10(8):. PubMed ID: 34439519
[TBL] [Abstract][Full Text] [Related]
4.
Kristiansson A; Örbom A; Ahlstedt J; Karlsson H; Zedan W; Gram M; Åkerström B; Strand SE; Altai M; Strand J; Vilhelmsson Timmermand O
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33579037
[TBL] [Abstract][Full Text] [Related]
5. Human Anti-Oxidation Protein A1M--A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy.
Ahlstedt J; Tran TA; Strand SE; Gram M; Åkerström B
Int J Mol Sci; 2015 Dec; 16(12):30309-20. PubMed ID: 26694383
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
[TBL] [Abstract][Full Text] [Related]
7. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
8. Recombinant α
Andersson CK; Shubbar E; Schüler E; Åkerström B; Gram M; Forssell-Aronsson EB
J Nucl Med; 2019 Nov; 60(11):1600-1604. PubMed ID: 30926650
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and pharmacokinetics of recombinant α1-microglobulin and its potential use in radioprotection of kidneys.
Ahlstedt J; Tran TA; Strand F; Holmqvist B; Strand SE; Gram M; Åkerström B
Am J Nucl Med Mol Imaging; 2015; 5(4):333-47. PubMed ID: 26269772
[TBL] [Abstract][Full Text] [Related]
10. Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice.
Svensson J; Mölne J; Forssell-Aronsson E; Konijnenberg M; Bernhardt P
Nucl Med Biol; 2012 Aug; 39(6):756-62. PubMed ID: 22445743
[TBL] [Abstract][Full Text] [Related]
11. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
12. PLGA nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: a novel approach towards reduction of renal radiation dose.
Arora G; Shukla J; Ghosh S; Maulik SK; Malhotra A; Bandopadhyaya G
PLoS One; 2012; 7(3):e34019. PubMed ID: 22442740
[TBL] [Abstract][Full Text] [Related]
13. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
Gupta SK; Singla S; Bal C
Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
[TBL] [Abstract][Full Text] [Related]
14. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
[TBL] [Abstract][Full Text] [Related]
16. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Kulkarni HR; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
[TBL] [Abstract][Full Text] [Related]
17. α
Kristiansson A; Davidsson S; Johansson ME; Piel S; Elmér E; Hansson MJ; Åkerström B; Gram M
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823731
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cytotoxic and tumor targeting capability of (177)Lu-DOTATATE-nanoparticles: a trailblazing strategy in peptide receptor radionuclide therapy.
Arora G; Dubey P; Shukla J; Ghosh S; Bandopadhyaya G
Ann Nucl Med; 2016 Jun; 30(5):334-45. PubMed ID: 26897009
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution, Pharmacokinetics, and Dosimetry of
Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
[TBL] [Abstract][Full Text] [Related]
20. Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration.
Melis M; Valkema R; Krenning EP; de Jong M
J Nucl Med; 2012 May; 53(5):749-53. PubMed ID: 22496587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]